## Chronotype is Associated with Sleep Quality in Older Adults

Scott C. Sauers;<sup>1</sup> Cristina D. Toedebusch;<sup>1</sup> Rachel Richardson;<sup>1</sup> Adam P. Spira;<sup>2,3,4</sup> John C. Morris;<sup>1,5</sup> David M. Holtzman;<sup>1,5,6</sup> Brendan P. Lucey<sup>1,6,7\*</sup>

<sup>1</sup>Department of Neurology, Washington University School of Medicine, St Louis, MO 63110

<sup>2</sup>Department of Mental Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

<sup>3</sup>Department of Psychiatry and Behavioral Sciences, The Johns Hopkins School of Medicine, Baltimore, MD 21205

<sup>4</sup>The Johns Hopkins Center on Aging and Health, Baltimore, MD 21205 <sup>5</sup>Knight Alzheimer Disease Research Center, Washington University School of Medicine, St Louis, MO 63110

<sup>6</sup>Center on Biological Rhythms and Sleep, Washington University School of Medicine, St Louis, MO 63110

<sup>7</sup>Hope Center for Neurological Disorders, Washington University School of Medicine, St Louis, MO 63110

\*corresponding author

Brendan P. Lucey, MD, MSCI Washington University School of Medicine Campus Box 8111 660 South Euclid Avenue St Louis, MO 63110 Phone: 314-747-3805 Fax: 314-747-3813 Email: <u>luceyb@wustl.edu</u>

## ABSTRACT

## Introduction:

Disrupted sleep is common in individuals with Alzheimer's disease (AD) and may be a marker for AD risk. The timing of sleep or chronotype affects sleep-wake activity and is also associated with AD, but little is known about links between sleep and chronotype in older adults. In this study, we tested if different measures of sleep and chronotype are associated among older adults even after adjusting for multiple potentially confounding variables.

## Methods:

Participants (N=243) with a mean age of 74 underwent standardized cognitive assessments, measurement of CSF AD biomarkers, and sleep monitoring via single-channel EEG, actigraphy, and self-reported sleep logs. Chronotype was defined as the midpoint of sleep measured by actigraphy.

## **Results:**

Later mid-point of sleep (i.e., late chronotype) was associated with African American race and greater night-to-night variability in the sleep mid-point. After controlling for age, race, sex, cognitive status, AD biomarkers, and sleep disorders, a later mid-point of sleep was associated with longer rapid eye movement (REM) onset latency, decreased REM sleep time, lower sleep efficiency, increased sleep onset latency, and more awakenings at night. Late

chronotype was also associated with increased <2 Hz non-REM slow-wave activity.

## **Conclusions:**

To identify individuals at risk for cognitive impairment before symptoms onset, non-invasive *in vivo* markers of brain function, such as sleep, are needed to track both future risk of cognitive impairment and response to interventions. Chronotype is a potential modifiable AD risk factor and should also be taken into account when using sleep as a marker for AD risk.

Keywords: chronotype, Alzheimer's disease, dementia, circadian rhythm, sleep quality, actigraphy

#### **INTRODUCTION**

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized neuropathologically by insoluble extracellular plagues of amyloid- $\beta$  (A $\beta$ ) and intracellular neurofibrillary tangles of hyperphosphorylated tau resulting in cognitive decline, dementia, and death.<sup>1</sup> AD is a growing public health crisis with the global prevalence of AD and other dementias expected to increase from 57 million cases as of 2019 to 153 million cases in 2050.<sup>2</sup> Amyloid pathology emerges ~15-20 years before synaptic dysfunction, neuronal loss, and subsequent cognitive decline.<sup>3</sup> Although there are many markers for AD pathology including the soluble cerebrospinal fluid (CSF) concentration of Aβ42,<sup>4</sup> the CSF and plasma Aβ42/40 ratio,<sup>5,6</sup> the levels of CSF and plasma p-tau species.<sup>7,8</sup> and radiotracers that bind to AB and tau via positron emission tomography (PET),<sup>9-11</sup> a major goal of the field is to develop AD biomarkers of brain function to identify individuals who are at risk for cognitive impairment before symptom onset. Sleep is a potential non-invasive in vivo marker of brain function that could be followed to track future risk of cognitive impairment as well as response to interventions such as anti-amyloid monoclonal antibodies.

Multiple measures of sleep and sleep disorders have been associated with an increased risk of AD or cognitive decline including poor self-reported sleep quality,<sup>12</sup> short or long sleep durations,<sup>13</sup> fragmented sleep,<sup>14</sup> decreased sleep efficiency,<sup>15</sup> increased wake after sleep onset,<sup>16</sup> increased sleep onset latency,<sup>17</sup> increased rapid eye movement (REM) sleep onset latency,<sup>18</sup> time spent in

different sleep stages,<sup>19,20</sup> sleep-disordered breathing,<sup>21</sup> and periodic limb movement during sleep.<sup>22</sup> Sleep and AD are hypothesized to have a bi-directional relationship with disrupted sleep contributing to the development of AD and AD pathology resulting in sleep disturbances.<sup>23,24</sup> Disrupted circadian rhythms are also associated with increased risk of AD and future risk of cognitive impairment. For instance, lower rest-activity rhythm amplitude is linked to AD and dementia.<sup>25</sup> Neurodegenerative diseases such as AD disrupt the circadian system leading to unpredictable rhythms and fragmented sleep. AD has been associated with delayed circadian phase.<sup>26,27</sup> Abnormalities in the phase of circadian rhythms and abnormalities in behavioral chronotype are also associated with risk or severity of AD.<sup>25,28</sup>

Chronotype is the body's natural time to sleep and regulates timing of sleep and wake activity.<sup>29</sup> The midpoint of sleep or the midpoint of time in bed may be measured by actigraphy or sleep logs, is analogous to the trough of the circadian rest-activity rhythm, and has been proposed as a measure of chronotype.<sup>30-34</sup> Chronotype is associated with a wide variety of diseases. In general, individuals with later chronotypes are at risk for worse health outcomes, including increased risk for dementia.<sup>27,35,36</sup> Mendelian randomization analyses suggest a causal role of late chronotype and increasing digestive tract cancer,<sup>37</sup> prostate cancer,<sup>38</sup> poor mental health,<sup>39</sup> and educational attainment,<sup>40,41</sup> as well as a role of cognitive function in causing later chronotype.<sup>42</sup> In the UK Biobank dataset, chronotype has a positive genetic correlation with educational attainment and intelligence, and a

negative genetic correlation with time spent outdoors, physical activity, and daytime napping.<sup>43</sup> Individuals with late chronotypes are more at risk for spinal, gastrointestinal, respiratory, and cardiovascular diseases, as well as depression, anxiety, personality disorders, substance use disorders, infertility, obesity, diabetes, insomnia, sleep apnea, and all-cause mortality.<sup>44</sup>

The potential to use sleep measures as a marker for AD risk is likely to be affected by timing of sleep or chronotype given the overlapping relationships between sleep, circadian rhythms, and AD. In this study, we tested if different measures of sleep and chronotype are related even after adjusting for multiple confounding variables such as age, sex, race, AD biomarkers, and cognitive status. We hypothesized that poorer measures of sleep quality (e.g., lower sleep efficiency) will be associated with late chronotype. If sleep measures are affected by chronotype, then chronotype may need to be taken into account when using sleep as a marker for AD risk. Chronotype may be a partial mediator or confound for a sleep measurement, which may lead to a spurious association with an outcome (e.g., AD pathology or cognitive deficit) if left unaccounted for. Further, this will also support chronotype as a potential modifiable AD risk factor.

## <u>METHODS</u>

## **Participants**

Data were gathered from 388 community-living participants enrolled in ongoing longitudinal studies at the Knight Alzheimer Disease Research Center (ADRC), Washington University in St. Louis. All individuals participating in Knight ADRC studies undergo annual standardized clinical and cognitive assessments. The Clinical Dementia Rating® (CDR®) was used to determine if participants were cognitively unimpaired (CDR 0), or mildly impaired (CDR 0.5). This study was approved by the Washington University in St. Louis Institutional Review Board. Each participant provided signed informed consent and was compensated for their participation.

## **Sleep Monitoring**

Sleep was recorded longitudinally at home for up to 6 nights using self-reported sleep logs, actigraphy (Actiwatch2, Philips Respironics) and a single-channel EEG device worn on the forehead (Sleep Profiler, Advanced Brain Monitoring). Sleep parameters were determined for the single-channel EEG, actigraphy, and sleep logs. Sleep-disordered breathing and periodic leg movements were measured using a home sleep apnea test (HSAT) device (Alice PDx, Philips Respironics), a device that was found to have 96.4% agreement with simultaneously recorded in-laboratory polysomnography.<sup>45</sup>

## Single-Channel EEG

Average total sleep time, time in non-REM (NREM) sleep stages 2 and 3 (time in NREM), time in REM sleep, sleep efficiency, and NREM slow wave activity (SWA) were measured as previously described.<sup>46</sup> Sleep efficiency was calculated based on the lights off and lights on times for the single-channel EEG studies and which were corroborated with actigraphy and sleep logs. Single-channel EEG sleep studies were visually scored by registered polysomnographic technologists using criteria adapted from the standard American Academy of Sleep Medicine (AASM) criteria.<sup>46</sup> Nights were excluded if >10% of the recording was artifactual and if the bed and rise times did not match the sleep log and/or actigraphy. All participants needed at least 2 nights of single-channel EEG monitoring that met these criteria to be included in the analysis. Time in NREM sleep stages 2 and 3 were combined, as the combined metric has a higher level of agreement with polysomnography.<sup>20</sup>

NREM SWA was calculated for each single-channel EEG study using MATLAB (MathWorks, Natick, MA), and the average NREM SWA in different frequency bins were used in the analysis. As previously described, a band-pass (two-way least-squares finite impulse response) filter between 0.5 and 40 Hz was applied to the single-channel EEG data. Spectral analysis was performed in consecutive 5-s epochs (Welch method, Hamming window, no overlap).<sup>20</sup> SWA power was calculated by averaging the power in the frequency bins of 0.5–1.0 Hz, 1.0-2.0 Hz, 2.0-3.0 Hz, and 3.0-4.0 Hz. To semi-automatically remove artifactual epochs,

power in the 20–30 Hz and 0.5–4.5 Hz bands for each electrode across all epochs of a recording were displayed. The operator (B.P.L.) then selected a threshold between the 95 and 99.5% threshold of power to remove artifactual epochs.

## Actigraphy

Actigraphy is commonly used to assess sleep and is validated against polysomnography.<sup>47</sup> Start and end times were set using a standardized protocol involving event marker button presses and sleep logs as previously described.<sup>48</sup> Actigraphic sleep parameters were calculated using Actiware 6.0 (Philips Respironics) and included: total sleep time, sleep efficiency, sleep onset latency, wake after sleep onset, and number of awakenings.

## Sleep Logs

Participants completed a sleep log for all nights that the single-channel EEG, actigraphy, and the HSAT were worn. Self-reported sleep parameters included total sleep time, sleep onset latency, and the number of awakenings during the night.

#### Home Sleep Apnea Test

Participants were monitored at home for one night to measure sleep-disordered breathing and periodic leg movements. The Alice PDx is a type III HSAT device that monitors oxygen saturation (SpO2) and pulse rate from an oximeter finger probe, nasal pressure-based airflow monitor and thermistor, thoracic and

abdominal effort via inductance plethysmography, bilateral electromyography sensors over the anterior tibialis muscles, and body position. Participants pressed the event button monitor at lights off and lights on. Bed and rise times were also confirmed with sleep logs and actigraphy as previously described.<sup>48</sup> In the morning, participants checked the "good study" indicator on the device to confirm a minimum of 4 hours of recording. A minimum of 4 hours of artifact-free recording was obtained for all participants and participants not meeting this criterion were asked to repeat monitoring. Respiratory events and periodic leg movements were scored by registered polysomnographic technologists using AASM criteria<sup>49</sup> and were reviewed by a board-certified sleep medicine physician (B.P.L.). The criteria for scoring hypopneas was a 4% decrease in oxygen saturation. The calculation of the Apnea-Hypopnea Index (AHI) and Periodic Leg Movement Index (PLMI) were calculated per hour of monitoring time for each participant. Participants using PAP therapy or dental devices were asked to use them as usual during the HSAT.

#### **Cerebrospinal fluid**

CSF was collected under a standardized protocol.<sup>50</sup> After overnight fasting, participants underwent a lumbar puncture at 8 AM and 20-30 ml of CSF was collected by gravity drip into a 50-ml conical tube using a 22-gauge atraumatic Sprotte spinal needle. The conical tube was then gently inverted to disrupt potential gradient effects and centrifuged at low speed to pellet any cellular debris. Samples were aliquoted (500 µl) in polypropylene tubes and stored at -

80°C until analysis. CSF Aβ40 and Aβ42, total tau (t-tau), and phosphorylated tau-181 were measured as previously described using an automated electrochemiluminescence immunoassay (Lumipulse, Fujirebio).<sup>51</sup>

## Chronotype

A participant's chronotype was defined as the average midpoint of the participant's sleep as measured by actigraphy. Actigraphy has previously been used to determine the midpoint of sleep.<sup>32,33</sup> The midpoint of sleep was calculated for individual nights based on bedtimes and risetimes, and then averaged for each participant. Midnight was set at "0" and times before midnight were negative (e.g., 11 PM = -1) and times after midnight were positive (e.g., 1 AM = +1). Participants were divided into equal groups of "early" and "late" chronotype depending on if they were before or after the average midpoint of sleep for the sample (3:04 AM). Forty-three participants also completed the Munich Chronotype Questionnaire (MCTQ)<sup>52</sup> that collects information on sleep-wake schedules during work and free days. The MCTQ is used to determine the midpoint of sleep and circadian phase. Comparison of the midpoint of sleep determined by actigraphy and the MCTQ found a high correlation (Supplementary Figure 1: r=0.823; p=1.278×10<sup>-11</sup>). Chronotype variability was also calculated as the standard deviation of an individual's chronotype across multiple nights of monitoring. Higher chronotype variability indicates greater night-to-night differences in the midpoint of sleep.

## Statistical analysis

Differences between chronotype groups were tested using Welch's 2-tailed t-test, or Chi-square if the data were categorical. Linear regression models tested if chronotype predicted different sleep variables after adjusting for age, sex, race, CDR, APOE4 status, CSF A $\beta$ 42/40, AHI, and PLMI. Only participants with each of these variables were included in the main analyses. Coding for dichotomous variables in the regression model is as follows: 1 = male, 2 = female; 0 = non-African American, 1 = African American (race determined by self-report); CDR negative (a score of 0) = 1, CDR positive (a non-zero score) = 2. All analyses were performed using R. Statistical significance was set at p = 0.05.

## **Data Availability**

Data to support the findings of this study are available from the corresponding author upon reasonable request. All code associated with this analysis is freely available from the corresponding author upon reasonable request.

## <u>RESULTS</u>

## **Participant Characteristics:**

Demographic and sleep parameter differences between late and early chronotype groups are shown in Tables 1, 2 and 3. Sex and age were not significantly different between early and late chronotype groups. African Americans were significantly more likely to have a late chronotype than non-African Americans and this relationship remained significant (p=0.007) after including participants who were missing other data and were not included in analyses using the fully adjusted model (totaling N=58 African Americans, N=293 non-African Americans). The distribution of chronotype by race, including these additional participants, is shown in Figure 1. Chronotype variability was also significantly higher in the late chronotype group.

Participants with later chronotypes had lower REM time, longer REM onset latency (Figure 2), and greater time in stages N2 and N3 (Table 2). Self-reported total sleep time, but not objective measures of sleep time measured by either EEG or actigraphy, was significantly longer in those with later chronotypes. <1 Hz and 1-2 Hz NREM slow-wave activity was higher in participants with late chronotype (Figure 3; Table 2). Notably, individuals with later chronotypes also had significantly greater between-night chronotype variability.

## **EEG sleep parameters:**

Multiple EEG-based sleep parameters have been associated with cognitive deficits and AD pathology. However, sleep may be confounded by factors such as age, sex, ApoE4+ status, amyloid pathology, and others.<sup>53-56</sup> Therefore, we adjusted for age, sex, race, CDR, ApoE4 status, CSF A $\beta$ 42/40 ratio, AHI, and PLMI to assess the relationship between EEG-derived sleep parameters and the midpoint of sleep (chronotype). In the fully adjusted model, later chronotype was associated with longer REM onset latency and shorter time in REM (Table 4). Longer REM onset latency was also associated with female sex, mild cognitive impairment, and ApoE4 status. In contrast, biomarker evidence of amyloid pathology was associated with decreased REM onset latency. Chronotype was not significantly associated with time in NREM stages 2 and 3, total sleep time, sleep efficiency, sleep onset latency, or wake after sleep onset (Table 4, 5).

#### Non-REM slow-wave activity:

The observed difference in NREM SWA between early and late chronotype (Figure 3; Table 2) could be due to other factors such as age, sex, and amyloid pathology. We tested this in the fully adjusted model and found that later chronotype was significantly associated with higher <1 Hz and 1-2 Hz NREM SWA (Table 6). Female sex was associated with higher NREM SWA in all frequency ranges. As previously reported,<sup>57,58</sup> lower NREM SWA (<1 Hz, 1-2 Hz, 2-3 Hz) was significantly correlated with lower CSF Aβ42/40 ratio (a marker for

amyloid deposition). African Americans also showed decreased <3 Hz NREM SWA.

## Actigraphy and self-reported sleep parameters:

For sleep parameters measured by actigraphy, lower sleep efficiency, longer sleep onset latency, and more awakenings were associated with later chronotype (Table 7). Interestingly, higher CDR and AHI were both significantly associated with lower sleep efficiency, longer sleep onset latency, and a greater number of awakenings showing significance. For self-report sleep parameters, later chronotype was associated with longer total sleep time and higher CDR (Table 8).

## **DISCUSSION**

In this study, later midpoint of sleep or chronotype was associated with measures reflecting poorer sleep quality such as lower time in REM sleep and longer REM onset latency. This association, however, differed depending on the sleep measurement method used. For instance, a late sleep midpoint was correlated with lower sleep efficiency on actigraphy but not on single-channel EEG. Since a greater number of nighttime awakenings measured by actigraphy were also associated with later midpoint of sleep, this suggests that individuals with later chronotype may have more restless sleep that does not result in wakefulness as recorded on EEG. Similarly, only self-reported total sleep time was related to later chronotype. Total sleep time measured by both actigraphy and single-channel EEG were not correlated with the midpoint of sleep.

Interestingly, <1 Hz and 1-2 Hz NREM SWA increased as the midpoint of sleep was delayed. This association was not observed at faster frequencies of 2-3 Hz and 3-4 Hz, and remained significant even after adjusting for multiple potential factors that affect NREM SWA including age, sex, and amyloid pathology (i.e., CSF A $\beta$ 42/40). Since individuals with later chronotype had evidence of poorer sleep quality (e.g., less time in REM sleep, lower sleep efficiency, greater nighttime awakenings), we hypothesize that higher NREM SWA may represent a homeostatic response to decreased sleep quality.

Individuals with a self-reported Black ethnic background have been reported to have earlier chronotypes than individuals of self-reported White ethnic background<sup>59</sup> and African Americans have been reported to have a shorter circadian period than European Americans.<sup>60</sup> In contrast, African American participants in our cohort had later chronotypes. For example, a study from the UK Biobank cohort found that a matched sample (N=2044; 50% self-reported Black ethnic background) with a mean age of 52 had a significantly greater prevalence of self-reported morning types based on a single question survey item in participants with self-reported Black ethnic background.<sup>59</sup> The current contrary finding could be due to the comparatively smaller sample size (9.9% African American in the current cohort), the increased age of participants in the present study (mean age = 74), a cohort effect such as geographical location or background characteristics, differences in factors included in each study's respective models (i.e., AD biomarkers such as CSF Aβ42/40), or methodological differences in identifying chronotype. The participants in the regression analyses may not be representative of the general population, with an educational attainment of 15.3 years among African Americans and 16.5 years among non-African Americans. Although only 24 African American participants completed a lumbar puncture and were included in the fully adjusted models, 63 participants had data available to calculate the midpoint of sleep and the same relationship was observed without adjusting for other factors.

These results indicate that midpoint of sleep or chronotype is associated with measures indicating poorer sleep quality. Since we calculated midpoint of sleep based on each individual's sleep behavior, we propose that this may be modified as part of a treatment plan to improve sleep quality. Chronotype can be modified by light exposure;<sup>61</sup> for example, exposure to 9,500 lux resulted in a shift of 4.5 hours earlier in young men.<sup>62</sup> Melatonin administration resulted in a shift 1.5 hours earlier.<sup>63</sup> Among subjects with delayed sleep phase syndrome, earlier sleep and wake times coupled with an attempt to avoid nighttime light exposure as well as napping resulted in a shift in chronotype of over 1 hour earlier in the absence of bright light therapy.<sup>64</sup>

CDR was significantly associated with multiple sleep variables, such as REM latency, sleep efficiency, sleep onset latency, awakenings as measured by actigraphy, and self-reported total sleep time. All of these variables were also significantly associated with chronotype. Further, each variable had the same direction of effect with CDR as it did with chronotype. That is, later chronotype and mild cognitive impairment are associated with overlapping aspects of sleep in similar ways. This suggests that the association of later chronotype and poor sleep quality may be related to cognitive dysfunction. Future studies are needed to assess if interventions to advance circadian phase improve measures of sleep quality and cognitive performance and/or behaviors associated with symptomatic AD such as the later-day agitation that is often referred to as sundowning.

Future research is needed to determine if an intervention to normalize very late chronotype results in improved sleep parameters such as REM sleep or decreased intra-night sleep/wake time variability. This could be accomplished through behavioral recommendations and education about the effects of abnormal sleep phase, bright light therapy beginning in the morning, limiting light exposure in the evening, modifying other zeitgebers such as exercise and meal timing, melatonin, or a combination thereof. Further research can also elucidate how inter-night variability in chronotype affects sleep quality and dementia, the interaction between chronotype and cognitive function in sleep outcomes, and the longitudinal association between chronotype and Alzheimer's disease biomarkers.

This study provides a detailed characterization of the association of the midpoint of sleep or chronotype with a range of sleep parameters in older adults with and without Alzheimer's disease symptomatology. Results indicate that a later midpoint of sleep is associated with different sleep parameters even after adjustment for potential confounding factors. Several of the sleep measures suggest that worse sleep quality (e.g., decreased time in REM sleep) is associated with later chronotype. However, the relationship of other sleep parameters is unclear and warrants further investigation. For instance, later chronotype is associated with higher NREM SWA. This may be due to an increased homeostatic response to poor sleep quality. NREM SWA has been proposed as a marker of brain function in individuals at risk for AD. Further

research is needed to establish the role of chronotype on NREM SWA and other sleep measures and if chronotype should be taken into account when assessing the effect of sleep on AD.

## **ACKNOWLEDGEMENTS**

We are indebted to the participants for their contributions to the study

## **FUNDING**

This work was funded by the National Institutes of Health (NIH) and National Institute on Aging (NIH/NIA) grant P01 AG03991.

## AUTHOR CONTRIBUTIONS

S.S.: Conception and design of the study; acquisition and analysis of data; drafted manuscript and figures; critically reviewed and approved the manuscript for publication.

C.D.T.: Acquisition and analysis of data; critically reviewed and approved the manuscript for publication.

R.R.: Acquisition and analysis of data; critically reviewed and approved the manuscript for publication.

A.P.S.: Critically reviewed and approved the manuscript for publication.

J.C.M.: Critically reviewed and approved the manuscript for publication.

D.M.H.: Critically reviewed and approved the manuscript for publication.

B.P.L.: Conception and design of the study; acquisition and analysis of data; drafted manuscript and figures; critically reviewed and approved the manuscript for publication.

## **DISCLOSURES**

S.S.: No conflicts.

C.D.T.: No conflicts.

R.R.: No conflicts.

A.P.S.: Received payment for serving as a consultant for Merck, received honoraria from Springer Nature Switzerland AG for guest editing special issues of *Current Sleep Medicine Reports*, and is a paid consultant to Sequoia Neurovitality.

J.C.M.: Receives research funding from NIH (P30 AG066444; P01AG003991;

P01AG026276; U19 AG024904). Neither Dr. Morris nor his family owns stock or has equity interest (outside of mutual funds or other externally directed accounts) in any pharmaceutical or biotechnology company.

D.M.H.: Co-founded and is on the scientific advisory board of C2N Diagnostics. D.M.H. is on the scientific advisory board of Denali, Genentech, and Cajal Neuroscience and consults for Asteroid.

B.P.L.: Receives research funding and consulting fees from Eisai; receives consulting fees and serves on a Data Safety and Monitoring Board for Eli Lilly; serves on the Scientific Advisory Board for Beacon Biosignals; receives consulting fees from OrbiMed and GLG Consulting; receives drug/matched placebo from Merck for a clinical trial funded by a private foundation.

## FIGURE LEGENDS

Figure 1: Distribution of midpoint of sleep by race. African Americans had a later midpoint of sleep (chronotype) than non-African Americans. Green = African American. Blue = non-African American.

Figure 2: Relationship of midpoint of sleep and REM sleep. As the midpoint of sleep (chronotype) became later in the night, average REM onset latency increased (A) and average time in REM sleep decreased (B).

Figure 3: Relationship of midpoint of sleep and NREM slow wave activity. Rounded to the nearest minute, the midpoint of sleep was separated into quantiles of 11:46 PM to 2:07 AM (first, leftmost), 2:07 AM to 2:38 AM (second), 2:38 AM to 3:03 AM (third), 3:03 AM to 3:28 AM (fourth), 3:28 AM to 3:55 AM (fifth), 3:55 AM to 10:04 AM (sixth, rightmost). <1 Hz and 1-2 Hz NREM slow wave activity (SWA) increased with later midpoint of sleep (A, B). The same relationship was not seen for 2-3 Hz NREM SWA (C) or 3-4 Hz (D).

# REFERENCES

1. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012; 367 (9): 795-804.

2. Prince M, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina M. World Alzheimer Report 2015: The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. London2015.

3. Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013; 12 (2): 207-216.

4. Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Amyloid-beta-42 in humans. Ann Neurol. 2006; 59 (3): 512-519.

5. Hansson O, Zetterberg H, Buchhave P, et al. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord. 2007; 23 (5): 316-320.

6. Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma beta-amyloid 42/40 predicts current and future brain amyloidosis. Neurology. 2019; 93 (17): e1647-e1659.

7. Fagan AM, Mintun MA, Shah AR, et al. Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med. 2009; 1 (8-9): 371-380.

8. Milà-Alomà M, Ashton NJ, Shekari M, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid- $\beta$  pathology in preclinical Alzheimer's disease. Nat Med. 2022; 28 (9): 1797-1801.

9. Mattsson-Carlgren N, Andersson E, Janelidze S, et al.  $A\beta$  deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. Sci Adv. 2020; 6 (16): eaaz2387.

10. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004; 55 (3): 306-3019.

11. Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016; 79: 110-119.

12. You JC, Jones E, Cross DE, et al. Association of  $\beta$ -amyloid burden with sleep dysfunction and cognitive impairment in elderly individuals with cognitive disorders. JAMA Netw Open. 2019; 2 (10): e1913383.

13. Chen JC, Espeland MA, Brunner RL, et al. Sleep duration, cognitive decline, and dementia risk in older women. Alzheimers Dement. 2016; 12 (1): 21-33.

14. Lim AS, Kowgier M, Yu L, Buchman AS, Bennett DA. Sleep fragmentation and the risk of incident Alzheimer's disease and cognitive decline in older adults. Sleep. 2013; 36 (7): 1027-1032.

15. D'Rozario AL, Chapman JL, Phillips CL, et al. Objective measurement of sleep in mild cognitive impairment: A systematic review and meta-analysis. Sleep Med Rev. 2020; 52: 101308.

16. Guarnieri B, Maestri M, Cucchiara F, et al. Multicenter Study on Sleep and Circadian Alterations as Objective Markers of Mild Cognitive Impairment and

Alzheimer's Disease Reveals Sex Differences. J Alzheimers Dis. 2020; 78 (4): 1707-1719.

17. Brown BM, Rainey-Smith SR, Villemagne VL, et al. The relationship between sleep quality and brain amyloid burden. Sleep. 2016; 39 (5): 1063-1068.

18. Zhang Y, Ren R, Yang L, et al. Sleep in Alzheimer's disease: a systematic review and meta-analysis of polysomnographic findings. Transl Psychiatry. 2022; 12 (1): 136.

19. Pase MP, Himali JJ, Grima NA, et al. Sleep architecture and the risk of incident dementia in the community. Neurology. 2017; 89 (12): 1244-1250.

20. Lucey BP, Wisch J, Boerwinkle AH, et al. Sleep and longitudinal cognitive performance in preclinical and early symptomatic Alzheimer's disease. Brain. 2021; 144 (9): 2852-2862.

21. Yaffe K, Laffan AM, Harrison SL, et al. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA. 2011; 306 (6): 613-619.

22. Leng Y, Blackwell T, Stone KL, Hoang TD, Redline S, Yaffe K. Periodic limb movements in sleep are associated with greater cognitive decline in older men without dementia. Sleep. 2016; 39 (10): 1807-1810.

23. Ju Y-E, Lucey BP, Holtzman DM. Sleep and Alzheimer disease pathology-a bidirectional relationship. Nat Rev Neurol. 2014; 10 (2): 115-119.

24. Lucey BP. It's complicated: The relationship between sleep and Alzheimer's disease in humans. Neurobiol Dis. 2020; 144: 105031.

25. Smagula SF, Gujral S, Capps CS, Krafty RT. A Systematic Review of Evidence for a Role of Rest-Activity Rhythms in Dementia. Front Psychiatry. 2019; 10: 778.

26. Volicer L, Harper DG, Manning BC, Goldstein R, Satlin A. Sundowning and circadian rhythms in Alzheimer's disease. Am J Psychiatry. 2001; 158 (5): 704-711.

27. Tranah GJ, Blackwell T, Stone KL, et al. Circadian activity rhythms and risk of incident dementia and mild cognitive impairment in older women. Ann Neurol. 2011; 70: 722-732.

28. Witting W, Kwa H, Eikelenboom P, Mirmiran M, Swaab D. Alterations in the circadian rest-activity rhythm in aging and Alzheimer's disease. Biol Psychiatry. 1990; 27 (6): 563-572.

29. Roenneberg T. What is chronotype? Sleep Biol Rhythms. 2012; 10 (2): 75-76.

30. Simpkin CT, Jenni OG, Carskadon MA, et al. Chronotype is associated with the timing of the circadian clock and sleep in toddlers. J Sleep Res. 2014; 23 (4): 397-405.

31. de Souza CM, Hidalgo MP. The midpoint of sleep on working days: a measure for chronodisruption and its association to individuals' well-being. Chronobiol Int. 2015; 32 (3): 341-348.

32. Santisteban JA, Brown TG, Gruber R. Association between the Munich Chronotype Questionnaire and Wrist Actigraphy. Sleep Disord. 2018; 2018: 5646848.

33. Refinetti R. Chronotype Variability and Patterns of Light Exposure of a Large Cohort of United States Residents. Yale J Biol Med. 2019; 92 (2): 179-186.

34. Urbanek JK, Spira AP, Di J, Leroux A, Crainiceanu C, Zipunnikov V. Epidemiology of objectively measured bedtime and chronotype in US adolescents and adults: NHANES 2003-2006. Chronobiol Int. 2018; 35 (3): 416-434.

35. Thapa N, Kim B, Yang JG, et al. The Relationship between Chronotype, Physical Activity and the Estimated Risk of Dementia in Community-Dwelling Older Adults. Int J Environ Res Public Health. 2020; 17 (10).

36. Satlin A, Volicer L, Stopa EG, Harper D. Circadian locomotor activity and corebody temperature rhythms in Alzheimer's disease. Neurobiol Aging. 1995; 16 (5): 765-771.

37. Yuan S, Mason AM, Titova OE, et al. Morning chronotype and digestive tract cancers: Mendelian randomization study. Int J Cancer. 2023; 152 (4): 697-704.

38. Sun X, Ye D, Jiang M, Qian Y, Mao Y. Genetically proxied morning chronotype was associated with a reduced risk of prostate cancer. Sleep. 2021; 44 (10).

39. Jones SE, Lane JM, Wood AR, et al. Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. Nat Commun. 2019; 10 (1): 343.

40. Hill WD, Marioni RE, Maghzian O, et al. A combined analysis of genetically correlated traits identifies 187 loci and a role for neurogenesis and myelination in intelligence. Mol Psychiatry. 2019; 24 (2): 169-181.

41. Lane JM, Vlasac I, Anderson SG, et al. Genome-wide association analysis identifies novel loci for chronotype in 100,420 individuals from the UK Biobank. Nat Commun. 2016; 7: 10889.

42. Wang J, Li YR, Jiang CQ, et al. Chronotype and cognitive function: Observational study and bidirectional Mendelian randomization. EClinicalMedicine. 2022; 53: 101713.

43. UKBB Genetic Correlation. <u>https://ukbb-rg.hail.is/rg\_browser/</u>. Accessed August 1, 2023.

44. Knutson KL, von Schantz M. Associations between chronotype, morbidity and mortality in the UK Biobank cohort. Chronobiol Int. 2018; 35 (8): 1045-1053.

45. Nilius G, Domanski U, Schroeder M, et al. A randomized controlled trial to validate the Alice PDX ambulatory device. Nat Sci Sleep. 2017; 9: 171-180.

46. Lucey BP, McLeland JS, Toedebusch CD, et al. Comparison of a single-channel EEG sleep study to polysomnography. J Sleep Res. 2016; 25 (6): 625-635.

47. Kushida CA, Chang A, Gadkary C, Guilleminault C, Carrillo O, Dement WC. Comparison of actigraphic, polysomnographic, and subjective assessment of sleep parameters in sleep-disordered patients. Sleep Med. 2001; 2: 389-396.

48. Toedebusch CD, McLeland JS, Schaibley CM, et al. Multi-modal home sleep monitoring in older adults. J Vis Exp. 2019; 143: e58823.

49. Iber C. *The AASM Manual for Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications: version 2.1.* Westchester, IL: American Academy of Sleep Medicine; 2014.

50. Schindler SE, Gray JD, Gordon BA, et al. Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging. Alzheimers Dement. 2018; 14: 1460-1469.

51. Kaplow J, Vandijck M, Gray J, et al. Concordance of Lumipulse cerebrospinal fluid t-tau/A $\beta$ 42 ratio with amyloid PET status. Alzheimers Dement. 2020; 16 (1): 144-152.

52. Roenneberg T, Wirz-Justice A, Merrow M. Life between clocks: daily temporal patterns of human chronotypes. J Biol Rhythms. 2003; 18 (1): 80-90.

53. Redline S, Kirchner HL, Quan SF, Gottlieb DJ, Kapur V, Newman A. The effects of age, sex, ethnicity, and sleep-disordered breathing on sleep architecture. Arch Intern Med. 2004; 164: 406-418.

54. Tranah GJ, Yaffe K, Nievergelt CM, et al. APOEɛ4 and slow wave sleep in older adults. PLoS One. 2018; 13 (1): e0191281.

55. Spira AP, Gamaldo AA, An Y, et al. Self-reported sleep and  $\beta$ -amyloid deposition in community-dwelling older adults. JAMA Neurol. 2013; 70 (12): 1537-1543.

56. Ju Y-E, McLeland JS, Toedebusch CD, et al. Sleep quality and preclinical Alzheimer's disease. JAMA Neurol. 2013; 70 (5): 587-593.

57. Mander BA, Marks SM, Vogel JW, et al.  $\beta$ -amyloid deposition in the human brain disrupts NREM slow wave sleep and associated hippocampus-dependent long-term memory. Nat Neurosci. 2015; 18 (7): 1051-1057.

58. Lucey BP, McCullough A, Landsness EC, et al. Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease. Sci Transl Med. 2019; 11 (474): eaau6550.

59. Malone SK, Patterson F, Lozano A, Hanlon A. Differences in morning-evening type and sleep duration between Black and White adults: Results from a propensity-matched UK Biobank sample. Chronobiol Int. 2017; 34 (6): 740-752.

60. Eastman CI, Suh C, Tomaka VA, Crowley SJ. Circadian rhythm phase shifts and endogenous free-running circadian period differ between African-Americans and European-Americans. Sci Rep. 2015; 5: 8381.

61. Rosenthal NE, Joseph-Vanderpool JR, Levendosky AA, et al. Phase-shifting effects of bright morning light as treatment for delayed sleep phase syndrome. Sleep. 1990; 13 (4): 354-361.

62. Boivin DB, Duffy JF, Kronauer RE, Czeisler CA. Dose-response relationships for resetting of human circadian clock by light. Nature. 1996; 379 (6565): 540-542.

63. Dodson ER, Zee PC. Therapeutics for Circadian Rhythm Sleep Disorders. Sleep Med Clin. 2010; 5 (4): 701-715.

64. Cole RJ, Smith JS, Alcalá YC, Elliott JA, Kripke DF. Bright-light mask treatment of delayed sleep phase syndrome. J Biol Rhythms. 2002; 17 (1): 89-101.

Table 1: Participant Characteristics			
	Early chronotype	Late chronotype	p-value
	Midpoint of sleep before 3:04 AM (n = 122)	Midpoint of sleep after 3:04 AM (n = 121)	-
Age at sleep study, years, mean (SD)	73.785 (4.996)	73.589 (5.536)	0.7717
Sex, number of females (%)	59 (48.361%)	68 (56.198%)	0.2213
Race, number of African Americans, n (%)	7 (5.738%)	17 (14.05%)	0.0299
Clinical Dementia Rating, n CDR+ (% = 0.5)	25 (20.492%)	22 (18.182%)	0.6485
APOE ε4 status: n APOE ε4+ (%)	45 (36.885%)	42 (34.711%)	0.724
CSF Aβ42/Aβ40 ratio Mean (SD) and then t-test	0.0687 (0.0233)	0.0734 (0.0226)	0.1754
Amyloid pathology, number Aβ+ (% CSF Aβ42/Aβ40 < 0.0673)	62 (50.82%)	51 (42.149%)	0.1085
AHI, number of respiratory events/h of monitoring time (%)			0.1798
None (<5)	47 (38.525%)	60 (49.587%)	
Mild (5-<15)	49 (40.164%)	40 (33.058%)	
Moderate (15-<30)	20 (16.393%)	18 (14.876%)	
Severe (≥30)	6 (4.918%)	3 (2.479%)	
PLMI, number of leg movements/h of monitoring time (%)			0.8073
None (<15)	56 (45.902%)	65 (53.719%)	
Low (15–<45)	39 (31.967%)	30 (24.793%)	
High (≥45)	27 (22.131%)	26 (21.488%)	
Chronotype variability, mean (SD)	0.526 (0.263)	0.658 (0.405)	0.00299
SD, Standard Deviation; CDR, Clinical Dementia Rating; ApoE4 status Apnea-Hypopnea Index; PLMI, Periodic Limb Movement Index	= apolipoprotein E ε4 positive ; CSF	cerebrospinal fluid; Aβ, amylo	id-beta; AHI,

Table 2: EEG Sleep Parameters			
	Early chronotype	Late chronotype	p-value
	Midpoint of sleep before 3:04 AM (n = 122)	Midpoint of sleep after 3:04 AM (n = 121)	-
Total sleep time, min, mean (SD)	371.7555 (57.798)	377.9669 (66.287)	0.4452
Sleep efficiency, %, mean (SD)	78.77617 (9.115)	78.24584 (9.871)	0.6693
Sleep onset latency, min, mean (SD)	17.19489 (11.865)	19.06408 (13.855)	0.2684
Wake after sleep onset, min, mean (SD)	141.076 (21.207)	144.8782 (29.037)	0.2454
N2 and N3 time, min, mean (SD)	254.2989 (51.253)	270.4797 (63.122)	0.03231
REM time, min, mean (SD)	81.13711 (25.163)	72.3852 (24.22)	0.007088
REM latency, min, mean (SD)	99.99076 (62.856)	128.29124 (78.748)	0.002652
NREM SWA <1 Hz, µV2/Hz, mean (SD)	58.04261 (40.302)	75.09838 (60.766)	0.01248
NREM SWA 1-2 Hz, µV2/Hz, mean (SD)	39.58187 (25.023)	49.44853 (33.736)	0.012
NREM SWA 2-3 Hz, μV2/Hz, mean (SD)	12.01186 (6.869)	13.5532 (7.187)	0.09507
NREM SWA 3-4 Hz, µV2/Hz, mean (SD)	5.332111 (2.825)	5.830836 (2.917)	0.1855
Min, Minutes; SD, Standard Deviation; N2, Stage N2 sleep; N3, Stage Activity; Hz, Hertz	e N3 sleep; REM, Rapid-Eye Mo	ovement sleep; NREM SWA, Non-F	REM Slow Wave

Table 3: Actigraphy and Self-Reported Sleep Parameters			
	Early chronotype	Late chronotype	p-value
	Midpoint of sleep before 3:04 AM (n = 122)	Midpoint of sleep after 3:04 AM (n = 121)	-
Actigraphic total sleep time, min, mean (SD)	390.8058 (51.996)	397.5094 (64.132)	0.3719
Actigraphic sleep efficiency, %, mean (SD)	81.65731 (7.291)	80.40583 (9.184)	0.2409
Actigraphic sleep onset latency, min, mean (SD)	19.73729 (15.659)	24.01861 (24.961)	0.1122
Actigraphic wake after sleep onset, min, mean (SD)	149.4696 (21.075)	153.4047 (29.456)	0.2327
Actigraphic number of awakenings, n, mean (SD)	32.65246 (12.499)	34.74959 (12.87)	0.1988
Self-reported total sleep time, min, mean (SD)	427.47408 (62.1)	446.27718 (69.78)	0.03165
Self-reported sleep onset latency, min, mean (SD)	25.52586 (23.949)	23.94115 (19.837)	0.5857
Self-reported number of awakenings, n, mean (SD)	2.126496 (1.143)	2.086725 (1.471)	0.8196
Min, minutes; SD, Standard Deviation	I		1

	Dependent Va	riables					
	Time in N2 ar	nd N3 (min)	N3 (min) Time in REM (min)		REM Onset Latency (min)		
Covariates	Estimate (β)	p-value	Estimate (β)	p-value	Estimate (β)	p-value	
Chronotype	4.385	0.150	-3.911	0.004	12.908	<0.001	
Age	0.890	0.220	-0.911	0.005	0.512	0.551	
Sex	21.287	0.004	2.035	0.530	47.839	<0.001	
Race	-29.311	0.021	-9.993	0.075	-25.951	0.084	
CDR	9.151	0.346	-4.525	0.292	40.501	<0.001	
ApoE4 Status	11.123	0.190	1.352	0.718	21.078	0.036	
Αβ42/40	0.329	0.999	-51.485	0.528	486.990	0.027	
AHI	-1.150	0.004	0.009	0.956	0.623	0.179	
PLMI	0.001	0.996	-0.039	0.571	0.331	0.073	

	Dependent Va	ariables						
	TST (min)		Sleep Efficier	ncy (%)	SOL (min)		WASO (min)	
Covariates	Estimate (β)	p-value	Estimate (β)	p-value	Estimate (β)	p-value	Estimate (β)	p-value
Chronotype	3.754	0.257	-0.790	0.128	0.761	0.278	1.792	0.191
Age	-0.003	0.997	-0.048	0.699	0.035	0.833	-0.069	0.830
Sex	23.347	0.004	0.701	0.574	6.147	<0.001	10.142	0.002
Race	-41.549	0.003	-3.289	0.128	1.176	0.687	-4.806	0.402
CDR	11.272	0.285	-0.893	0.589	1.875	0.401	4.483	0.290
ApoE4 Status	9.077	0.324	0.692	0.631	-0.355	0.855	4.853	0.201
Αβ42/40	-169.20	0.399	-25.405	0.419	41.176	0.332	-29.508	0.720
AHI	-0.377	0.375	-0.155	0.020	0.045	0.619	-0.138	0.427
PLMI	0.002	0.990	0.006	0.822	-0.029	0.416	-0.056	0.416

Table 6: NREM SI	ow Wave Activity	,										
	Dependent Variables											
Covariates	<1 Hz		1-2 Hz		2-3 Hz		3-4 Hz					
	Estimate (β)	p-value	Estimate (β)	p-value	Estimate (β)	p-value	Estimate (β)	p-value				
Chronotype	8.119	0.002	3.249	0.030	0.015	0.967	-0.107	0.468				
Age	1.299	0.037	0.559	0.118	0.049	0.564	0.030	0.397				
Sex	39.557	<0.001	24.624	<0.001	6.002	<0.001	2.273	<0.001				
Race	-22.387	0.039	-13.254	0.033	-2.893	0.049	-1.019	0.097				
CDR	9.555	0.252	4.889	0.308	0.607	0.593	0.224	0.636				
ApoE4 Status	10.460	0.148	4.008	0.335	0.337	0.732	0.222	0.588				
Αβ42/40	523.810	0.001	295.770	0.001	48.137	0.025	10.627	0.234				
AHI	0.264	0.427	0.057	0.765	-0.037	0.414	-0.022	0.246				
PLMI	0.126	0.342	0.101	0.184	0.032	0.077	0.010	0.196				
NREM, non-rapid e Hypopnea Index; P	eye movement; CD PLMI, Periodic Limb	R, Clinical De Movement li	ementia Rating; Apo ndex; Hz, Hertz	eE4 status = a	polipoprotein Ε ε4	positive; AH	l, Aβ, amyloid-bet	a; Apnea-				

Table 7: Actigrap	hy Sleep Var	iables											
	Dependent Variables												
	TST (min)		Sleep Efficiency (%)		SOL (min)		WASO (mi	WASO (min)		(#)			
Covariates	Estimate (β)	p-value	Estimate (β)	p-value	Estimate (β)	p-value	Estimate (β)	p-value	Estimate (β)	p-value			
Chronotype	4.806	0.117	-0.958	0.022	2.897	0.007	1.739	0.208	2.215	0.001			
Age	0.423	0.557	-0.050	0.611	-0.036	0.888	-0.032	0.920	0.054	0.723			
Sex	25.581	0.001	1.527	0.127	-0.393	0.879	9.470	0.005	-2.460	0.111			
Race	-32.334	0.012	-2.821	0.107	2.639	0.557	-4.493	0.438	-0.233	0.931			
CDR	-16.333	0.085	-6.577	<0.001	13.740	<0.001	3.885	0.364	6.363	0.002			
ApoE4 Status	9.144	0.281	0.057	0.960	1.729	0.561	5.244	0.171	-0.637	0.720			
Αβ42/40	65.202	0.724	7.930	0.752	-61.213	0.346	-32.179	0.699	4.387	0.910			
AHI	-0.634	0.104	-0.185	0.001	0.417	0.003	-0.186	0.289	0.411	<0.001			
PLMI	-0.204	0.186	-0.029	0.174	0.076	0.159	-0.053	0.443	-0.013	0.696			
TST, Total Sleep Ti apolipoprotein Ε ε <sup>2</sup>	me; SOL, Sle positive ; AF	ep Onset La II, Apnea-Hy	tency; WASO, ' popnea Index; l	Wake After S PLMI, Period	leep Onset; n lic Limb Move	nin, minutes; ment Index; A	CDR, Clinical λβ, amyloid-be	Dementia Ra ta	ting; ApoE4 stat	tus =			

	Dependent Varia	ables				
Covariates	TST (min)		SOL (min)		Awakenings (#)	1
	Estimate (β)	p-value	Estimate (β)	p-value	Estimate (β)	p-value
Chronotype	14.678	<0.001	-0.285	0.814	-0.002	0.978
Age	-0.583	0.492	0.538	0.059	0.001	0.953
Sex	0.967	0.911	11.842	<0.001	0.210	0.242
Race	-15.484	0.323	-5.473	0.301	-0.336	0.302
CDR	25.902	0.023	-2.511	0.509	-0.051	0.830
ApoE4 Status	14.444	0.150	1.957	0.560	-0.047	0.823
Αβ42/40	24.186	0.911	110.542	0.127	0.535	0.907
AHI	0.009	0.984	0.009	0.956	0.011	0.260
PLMI	-0.023	0.898	-0.002	0.973	-0.001	0.826

# Chronotype Distribution by Race



Midpoint of Sleep (Chronotype)



